The comparison matters because breast cancer risk assessment in primary care often begins with a deceptively simple question: does a patient’s family history meet the threshold for referral? NICE guidance provides structured criteria based largely on patterns such as the number of relatives affected, their ages at diagnosis, and the presence of breast, ovarian, prostate or related cancers within a family. These rules are intended to be practical and safe, but they necessarily compress complex biological and genealogical information into a set of clinical decision points.

BOADICEA approaches the same problem as a mathematical risk calculation. The model was developed to combine multiple sources of evidence, including family history, inherited pathogenic variants in genes such as BRCA1, BRCA2 and other susceptibility genes, and broader genetic influences. In suitable versions of the model, these can be integrated with personal and reproductive factors and, where available, information such as polygenic risk scores. Instead of producing only a yes-or-no referral decision, BOADICEA can generate estimates of a woman’s future breast cancer risk and the likelihood that she carries a clinically important genetic variant.

The new analysis focuses specifically on women younger than 50 in primary care, a group for whom risk assessment can be particularly challenging. Breast cancer is less common at younger ages than later in life, yet an early diagnosis can be a warning sign of inherited susceptibility. A family history may also appear unremarkable when relatives are few, records are incomplete, family members are male, or individuals died before developing cancer. Conversely, a large family with several late-onset cancers may look alarming without necessarily indicating a highly penetrant inherited mutation.

That difference creates the possibility of disagreement between guideline-based assessment and multifactorial modelling. A woman who does not satisfy a conventional NICE referral threshold might nevertheless receive a meaningful risk estimate from BOADICEA if her available genetic and family information points toward elevated susceptibility. The reverse could also occur: a referral triggered by a recognizable family-history pattern might produce a lower calculated risk when the model accounts for additional details. Such discordance is central to the study’s clinical importance because every referral involves time, specialist capacity, genetic counselling resources and, for patients, potential anxiety and additional testing.

Risk models do not replace clinical judgement, and their output is only as reliable as the information entered. Family-history data can be incomplete or inaccurate, particularly when relatives have been adopted, estranged, diagnosed in different healthcare systems or recorded under nonspecific cancer labels. Genetic test results also require careful interpretation. A pathogenic variant can substantially change risk management, while a variant of uncertain significance should not be treated as proof of inherited disease. BOADICEA therefore functions best as a decision-support tool rather than an automated verdict.

The study’s primary-care setting is especially significant as health services move toward earlier and more personalized cancer prevention. General practitioners and other primary-care professionals are often the first to hear about a family history, but they may have limited time to construct detailed pedigrees or calculate lifetime cancer probabilities. A model that can be integrated into electronic records or a clinical risk platform could help standardize assessment, highlight missing information and identify patients who merit genetic counselling, enhanced surveillance or preventive discussion.

At the same time, a more sensitive approach must be balanced against the risk of over-referral. Sending every woman with a relative diagnosed with breast cancer to specialist services could overwhelm clinics and expose many people to investigations that are unlikely to change their care. The value of comparing NICE with BOADICEA is therefore not simply to determine which method produces more referrals. It is to examine whether the two systems identify the same women, where they diverge, and whether a combination of transparent guidelines and individualized risk prediction can improve the precision of primary-care triage.

The findings could influence how inherited breast cancer risk is recognized before a diagnosis occurs, particularly among younger women whose family histories fall into a grey zone. If multifactorial modelling identifies clinically important risk that guideline thresholds miss, it could support a broader, more data-driven route into specialist assessment. If the model adds little beyond existing criteria, its use might be better targeted to selected cases. Either outcome would help clarify how genetic information, family history and population-level guidance should work together as breast cancer prevention becomes increasingly personalized. The study by Frost, Ficorella, Berrington de Gonzalez and colleagues provides evidence for that debate and highlights a rapidly emerging question in modern medicine: can algorithms make inherited cancer risk assessment more accurate without making it less understandable?

Subject of Research: Comparison of NICE criteria and the BOADICEA multifactorial risk model for breast cancer risk assessment and referral among women under 50 in primary care.

Article Title: Comparison of NICE criteria with the BOADICEA multifactorial risk model to guide breast cancer risk assessment and referral amongst women under age 50 within primary care.

Article References: Frost, R., Ficorella, L., Berrington de Gonzalez, A. et al. “Comparison of NICE criteria with the BOADICEA multifactorial risk model to guide breast cancer risk assessment and referral amongst women under age 50 within primary care.” British Journal of Cancer (2026). https://doi.org/10.1038/s41416-026-03547-2

Image Credits: AI Generated

DOI: 10.1038/s41416-026-03547-2

Keywords: breast cancer, BOADICEA, NICE guidelines, genetic risk, inherited cancer, primary care, breast cancer risk assessment, genetic counselling, BRCA1, BRCA2, precision medicine

At the core of this research lies the intricate behavior of ILC, a histological variant of breast cancer distinct in its growth and metastatic characteristics. Unlike the more common invasive ductal carcinoma, ILC is notorious for its diffuse infiltration patterns that often elude conventional imaging techniques. The integration of ^18F-FDG PET-CT offers a promising solution by combining metabolic and anatomical insights, allowing for a more sensitive detection of malignant lesions. This technique utilizes ^18F-FDG, a glucose analog tagged with a positron-emitting radioisotope, which accumulates preferentially in hypermetabolic cancer cells, thereby illuminating active disease sites invisible to traditional imaging.

The correction issued by Metser, Dayes, Parpia, and colleagues underscores the importance of precise calibration and interpretation parameters for ^18F-FDG PET-CT in staging locally advanced ILC. Initially, some discrepancies were noted in the sensitivity and specificity values reported, which are now clarified to provide a more accurate reflection of the modality’s diagnostic performance. This rectification is crucial because it directly impacts treatment planning, guiding decisions about surgical intervention, systemic therapy, and radiation.

One of the pivotal insights of the updated findings is the adjusted sensitivity range of ^18F-FDG PET-CT in detecting both primary tumors and regional lymph node involvement in ILC patients. Due to the lower glycolytic activity typical of ILC cells compared to other breast cancer types, the uptake of ^18F-FDG has historically been variable. The revised data now better delineate which subgroups of patients benefit most from PET-CT imaging, particularly those with bulky or multifocal disease, aiding clinicians in stratifying risk and optimizing therapeutic regimens.

Furthermore, the correction details technical refinements in image acquisition protocols, including adjustments to the time interval between ^18F-FDG injection and image capture, as well as enhancements in the resolution of PET detectors. Such improvements have a profound effect on lesion detectability, especially in the context of small or diffuse infiltrative tumors characteristic of ILC. By capturing more precise images, clinicians can now detect occult metastases that would have otherwise gone unnoticed, thereby redefining disease staging and prognosis.

Beyond diagnostic accuracy, this study correction brings to the forefront the potential of ^18F-FDG PET-CT as a predictive tool for treatment response. The metabolic changes observed via PET scanning during neoadjuvant therapies can offer early indications of therapeutic efficacy or resistance. This capability is particularly vital for ILC patients, whose tumors often demonstrate heterogeneous responses to chemotherapy. By integrating metabolic imaging into treatment monitoring, oncologists can tailor interventions more precisely, possibly sparing patients from ineffective treatments and their associated toxicities.

The implications of this research also extend to surgical planning. Accurate staging influences the extent of surgery, from breast-conserving techniques to mastectomy, and informs the need for axillary lymph node dissection versus sentinel node biopsy. The enhanced visualization of disease burden by ^18F-FDG PET-CT supports more conservative approaches in selected cases, aligning with the modern paradigm of personalized oncologic care.

Importantly, the correction addresses previously underreported incidences of false positives and negatives, emphasizing the necessity for correlating PET-CT results with histopathological findings and other imaging modalities such as MRI and ultrasound. This multidisciplinary validation underscores that while ^18F-FDG PET-CT enhances diagnostic confidence, it should be integrated within a comprehensive diagnostic framework rather than employed in isolation.

The study also canvasses the biological underpinnings contributing to variable ^18F-FDG avidity in ILC. Factors such as tumor cellularity, expression of glucose transporters, and the microenvironmental milieu impact radiotracer uptake. Recognizing these variables not only informs imaging interpretation but could pave the way for novel radiotracers tailored to ILC’s unique metabolic profile, potentially overcoming current limitations of ^18F-FDG PET-CT.

Moreover, the updated findings highlight the critical timing of PET-CT in the diagnostic algorithm. Optimal staging is recommended prior to the initiation of systemic therapies to avoid confounding effects of treatment-induced metabolic changes. Additionally, the study suggests that serial imaging could be beneficial in long-term surveillance, especially given ILC’s propensity for late recurrences.

Clinically, this correction may stimulate revisions in guidelines pertaining to breast cancer staging. Currently, ^18F-FDG PET-CT is not universally standard for routine evaluation of ILC, partly due to inconsistent data. The clarified efficacy and technical recommendations presented here could encourage broader adoption, ultimately improving patient outcomes by facilitating earlier and more accurate detection of disease extent.

On a translational research front, this correction reiterates the vital role of prospective, well-controlled studies in validating imaging biomarkers and techniques. It reinforces the need for large-scale multicenter collaborations to verify findings across diverse populations and technological platforms, ensuring that advancements are robust and generalizable.

In conclusion, the correction to this prospective study on ^18F-FDG PET-CT for staging locally advanced invasive lobular breast carcinoma marks a pivotal enhancement in the realm of breast cancer diagnostics. It fortifies the evidence base supporting the nuanced role of metabolic imaging in managing a notoriously elusive cancer subtype. As technology evolves and our understanding deepens, such meticulous updates are essential for refining clinical pathways and empowering oncologists to deliver precision medicine with ever greater confidence.

This advancement underscores the intersection of molecular imaging and oncology as a fertile ground for innovation. By continuously improving detection accuracy, treatment planning, and monitoring through enhanced PET-CT protocols, the oncology field moves closer to the goal of individualized, effective, and patient-centered care achievable for those facing invasive lobular breast carcinoma.

Subject of Research: Nuclear medicine imaging techniques, specifically ^18F-FDG PET-CT, for staging locally advanced invasive lobular breast carcinoma.

Article Title: Correction: Prospective study on ^18F-FDG PET-CT for staging locally advanced invasive lobular breast carcinoma.

Article References: Metser, U., Dayes, I.S., Parpia, S. et al. Correction: Prospective study on ^18F-FDG PET-CT for staging locally advanced invasive lobular breast carcinoma. Br J Cancer (2026). https://doi.org/10.1038/s41416-026-03435-9

Image Credits: AI Generated